A review published in
Genes & Diseases examines a pathway that can both protect the liver and contribute to its destruction. Researchers at Tongji Hospital, Huazhong University of Science and Technology, describe how
FGF19–FGFR4 signalling regulates metabolism and tissue repair, while abnormal activation can promote liver cancer and complicate treatment.
The pathway connects signals from the intestine with responses in the liver.
Fibroblast growth factor 19, or FGF19, binds to its receptor
FGFR4 with help from a protein called
β-Klotho. This interaction helps control bile acid production, glucose handling, and fat metabolism, maintaining processes essential for liver health.
Bile acids support digestion, but excessive accumulation can damage tissues. FGF19 acts as part of a feedback system that limits their production. The review also examines the pathway’s involvement in liver regeneration and its changing roles in metabolic dysfunction-associated steatotic liver disease, alcohol-related liver disease, and conditions involving impaired bile flow.
These protective functions have encouraged research into therapies that mimic FGF19. The review describes clinical studies of
aldafermin, an engineered FGF19 analogue, reporting reductions in liver fat and improvements in some measures of liver disease and fibrosis. However, diarrhoea and potential cancer-promoting effects observed in certain animal models highlight the need for safety assessment.
In
hepatocellular carcinoma, the most common primary liver cancer, excessive FGF19–FGFR4 activity can support tumour cell survival, spread, immune suppression, and resistance to treatment. This creates a different therapeutic goal: blocking the pathway rather than enhancing its metabolic effects.
Selective FGFR4 inhibitors offer one potential approach. In an early clinical trial summarised in the review,
fisogatinib produced responses in
17% of patients with FGF19-positive tumours, compared with none in the FGF19-negative group. The finding supports investigating tumour FGF19 expression as a marker for selecting patients who might benefit.
The review also explores combinations with
immunotherapy and other anticancer agents. Experimental studies suggest these strategies could strengthen tumour control, although clinical evidence remains limited. Acquired mutations in FGFR4 can cause drug resistance, reinforcing the need for inhibitors and better treatment selection.
A central challenge is separating metabolic benefits from signals that stimulate unwanted cell growth. Future research must clarify how disease stage, tissue context, and interactions with other pathways determine whether FGF19–FGFR4 activity is protective or harmful.
# # # # # #
Genes & Diseases publishes rigorously peer-reviewed and high quality original articles and authoritative reviews that focus on the molecular bases of human diseases. Emphasis is placed on hypothesis-driven, mechanistic studies relevant to pathogenesis and/or experimental therapeutics of human diseases. The journal has worldwide authorship, and a broad scope in basic and translational biomedical research of molecular biology, molecular genetics, and cell biology, including but not limited to cell proliferation and apoptosis, signal transduction, stem cell biology, developmental biology, gene regulation and epigenetics, cancer biology, immunity and infection, neuroscience, disease-specific animal models, gene and cell-based therapies, and regenerative medicine.
Scopus CiteScore: 10.4 |Impact Factor:14.6
# # # # # #
More information: https://www.keaipublishing.com/en/journals/genes-and-diseases/
Editorial Board: https://www.keaipublishing.com/en/journals/genes-and-diseases/editorial-board/
All issues and articles in press are available
online in
ScienceDirect (
https://www.sciencedirect.com/journal/genes-and-diseases).
Submissions to
Genes & Diseases may be made using
Editorial Manager (
https://www.editorialmanager.com/gendis/default.aspx).
Print ISSN: 2352-4820
eISSN: 2352-3042
CN: 50-1221/R
Contact Us: editor@genesndiseases.cn
X (formerly twitter): @GenesNDiseases (
https://x.com/GenesNDiseases)
# # # # # #
Zhangfan Wu, Yijun Wang, Jiaqian Zhang, Siwen Li, Junjie Wen, Dian Hu, Junqing Jiang, Zerui Zhang, Xiangyuan Luo, Limin Xia, The role of FGF19–FGFR4 signaling pathway in liver health and disease: Guardian or destroyer, Genes & Diseases, Volume 13, Issue 6, 2026, 101989,
https://doi.org/10.1016/j.gendis.2025.101989
Funding
National Natural Science Foundation of China
U23A20451
National Natural Science Foundation of China
82273310
Natural Science Foundation of Hubei Province, China
2022CFA016
Basic Research Support Program of Huazhong University of Science and Technology (China)
2023BR038